PDT, thus, was initially developed for ocular use to treat neovascular age-related macular degeneration (nAMD) [2], however this indication has been superseded by anti-vascular endothelial growth factor (anti-VEGF) therapies for nAMD. This evidence concerns the gene VEGFA and wet macular degeneration.